tiprankstipranks
MacroGenics Inc (CH:M55)
NASDAQ:M55
Switzerland Market
M55
MacroGenics
RESEARCH TOOLSreports

MacroGenics (M55) Earnings Dates, Call Summary & Reports

0 Followers

Earnings Data

Report Date
Aug 11, 2026
TBA (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
0.02
Last Year’s EPS
-0.46
Same Quarter Last Year
Analyst Consensus
Moderate Buy
Based on 4 Analysts Ratings

Earnings Call Summary

Q4 2024
Earnings Call Date:Mar 20, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
MacroGenics achieved significant clinical and financial milestones in 2024, marked by a substantial increase in revenues and strong progress in clinical trials. However, increased net losses and operating expenses, along with the discontinuation of vobra duo, present challenges. The company remains financially stable with a solid cash position and is poised for future growth.
Company Guidance
In the conference call, MacroGenics provided guidance and updates on their financial and clinical developments for the year 2024 while highlighting expectations for 2025. The company reported a total revenue of $150 million for 2024, a significant increase from $58.7 million in 2023, largely due to milestone achievements under the Incyte License Agreement. Research and development expenses rose to $177.2 million, up from $166.6 million in the previous year, reflecting increased costs related to their ADC pipeline and clinical trials. Cash, cash equivalents, and marketable securities totaled $201.7 million at the end of 2024, ensuring a cash runway into the second half of 2026. Clinically, MacroGenics provided updates on their investigational therapies, including the completion of enrollment in the 150-patient LORIKEET Phase 2 trial for lorigerlimab and plans to initiate the LINNET Phase 2 study in mid-2025. Additionally, three ADC molecules are in various stages of development, with MGC026 and MGC028 in clinical trials and MGC030 in preclinical studies. The company is also advancing MGD024, a bi-specific DART molecule, with ongoing Phase 1 studies.
Significant Revenue Growth
MacroGenics reported a total revenue of $150 million for the year ended December 31, 2024, compared to $58.7 million in 2023, primarily due to milestones achieved under the Incyte License Agreement.
Clinical Milestones in 2024
MacroGenics completed enrollment in the LORIKEET Phase 2 trial for lorigerlimab and initiated the LINNET Phase 2 study. The company also advanced its ADC portfolio with MGC026, MGC028, and MGC030.
Strong Financial Position
Cash, cash equivalents, and marketable securities balance was $201.7 million as of December 31, 2024, with projections extending the cash runway into the second half of 2026.
Successful Asset Sale
Completed the sale of MARGENZA to TerSera Therapeutics, yielding a $36.3 million gain and providing non-dilutive capital.

MacroGenics (CH:M55) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
Daily Earnings Calendar >

CH:M55 Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 11, 2026
2026 (Q2)
0.02 / -
-0.459―――
May 13, 2026
2026 (Q1)
-0.46 / -0.47
-0.52310.77% (+0.06)――
Mar 09, 2026
2025 (Q4)
-0.10 / -0.19
-0.1934.17% (<+0.01)――
Nov 12, 2025
2025 (Q3)
-0.36 / 0.22
0.724-70.00% (-0.51)――
Aug 14, 2025
2025 (Q2)
-0.34 / -0.46
-0.71635.96% (+0.26)――
May 13, 2025
2025 (Q1)
-0.58 / -0.52
-0.67622.62% (+0.15)――
Mar 20, 2025
2024 (Q4)
-0.22 / -0.19
-0.59567.57% (+0.40)―
Nov 05, 2024
2024 (Q3)
0.17 / 0.72
0.225221.43% (+0.50)―
Aug 06, 2024
2024 (Q2)
-0.53 / -0.72
0.74-196.74% (-1.46)――
May 09, 2024
2024 (Q1)
-0.52 / -0.68
-0.491-37.70% (-0.19)―
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

FAQ

When does MacroGenics Inc (CH:M55) report earnings?
MacroGenics Inc (CH:M55) is schdueled to report earning on Aug 11, 2026, TBA (Confirmed).
    What is MacroGenics Inc (CH:M55) earnings time?
    MacroGenics Inc (CH:M55) earnings time is at Aug 11, 2026, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of MacroGenics Inc stock?
          The P/E ratio of MacroGenics is N/A.
            What is CH:M55 EPS forecast?
            CH:M55 EPS forecast for the fiscal quarter 2026 (Q2) is 0.02.